Icotinib/osimertinibAcquired resistance: 2 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2021年 / 1853卷 / 1期

关键词：

D O I：

10.1007/s40278-021-95099-1

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：233 / 233

相关论文

共 50 条

[41] Icotinib/rivoceranibVarious toxicities: 3 case reports
Reactions Weekly, 2018, 1705 (1) : 156 - 156
[42] Erlotinib/osimertinibAcquired drug resistance: case report
Reactions Weekly, 2020, 1826 (1) : 127 - 127
[43] OsimertinibAcquired resistance in lung adenocarcinoma: case report
Reactions Weekly, 2019, 1735 (1) : 205 - 205
[44] OsimertinibAcquired resistance
Reactions Weekly, 2024, 2003 (1) : 666 - 666
[45] Icotinib/osimertinibDrug resistance: case report
Reactions Weekly, 2023, 1962 (1) : 214 - 214
[46] OsimertinibAcquired resistance to osimertinib therapy: case report
Reactions Weekly, 2018, 1707 (1) : 217 - 217
[47] Afatinib/gefitinib/osimertinibAcquired resistance: case report
Reactions Weekly, 2020, 1810 (1) : 18 - 18
[48] Erlotinib/osimertinibAcquired clinical drug resistance: case report
Reactions Weekly, 2022, 1899 (1) : 185 - 185
[49] Gefitinib/osimertinibAcquired resistance in lung adenocarcinoma: case report
Reactions Weekly, 2018, 1713 (1) : 177 - 177
[50] Multiple drugsAcquired resistance to erlotinib, gefitinib and icotinib and various other toxicities: 11 case reports
Reactions Weekly, 2019, 1767 (1) : 225 - 225

← 1 2 3 4 5 →